NCAM1 and neoplasm: Interestingly, some preliminary data have shown a good tolerability profile of the combination treatment, activation of immune cells including CD56+CD16– PB-NK cells and a trend towards higher numbers of tumor-associated NKp46+ NK cells together with significantly higher numbers of tumor-associated CD8+ T cells (45) (NCT02671435).